MacroGenics
Developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | - | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (23 %) | 101 % | (62 %) | 159 % | (38 %) | - | (25 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (268 %) | (80 %) | (260 %) | (63 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (267 %) | (79 %) | (16 %) | (45 %) | (142 %) | (129 %) | (316 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 284 % | 136 % | 291 % | 119 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
MacroGenics is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative monoclonal antibody-based treatments for cancer. Monoclonal antibodies are lab-made molecules that can mimic the immune system's ability to fight off harmful pathogens such as viruses and bacteria. MacroGenics focuses on creating these antibodies to target and treat various types of cancer, particularly those with unmet medical needs.
The company operates in the biotechnology and pharmaceutical markets, primarily serving patients who suffer from cancer. Their clients include healthcare providers, hospitals, and research institutions that are involved in cancer treatment and research. MacroGenics' business model revolves around research and development (R&D) of new drugs, conducting clinical trials to test their efficacy and safety, and eventually bringing these drugs to market either independently or through partnerships with larger pharmaceutical companies.
MacroGenics makes money through several channels. Initially, they invest heavily in R&D to develop new drug candidates. Once these candidates show promise, they enter clinical trials, which are often funded through a mix of internal resources and external partnerships. If a drug successfully passes through clinical trials and receives regulatory approval, MacroGenics can then commercialize it, generating revenue through sales. Additionally, the company may enter into licensing agreements or partnerships with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales.
The company is currently expanding its pipeline of drug candidates and has recently operationalized a new Good Manufacturing Practice (GMP) manufacturing suite. This facility ensures that their products are produced to the highest standards of quality and safety. They are also actively recruiting additional manufacturing and quality professionals to support this growth.
Keywords: Biopharmaceutical, Monoclonal Antibodies, Cancer Treatment, Clinical Trials, Drug Development, Biotechnology, Pharmaceutical, GMP Manufacturing, Oncology, R&D.